FDA approves Genentech drug for advanced lung cancer

Published On 2015-12-13 09:09 GMT   |   Update On 2015-12-13 09:09 GMT
Advertisement
The Food and Drug Administration has approved an experimental Genetech drug for patients with a certain type of lung cancer who have few other options.

Alecensa (AL'-eh-sehn-sah) was approved for patients with advanced non-small cell lung cancer with a mutation in a gene called ALK who have relapsed after treatment with Pfizer Inc.'s Xalkori or who could not tolerate that drug.

The mutation in ALK, or anaplastic lymphoma kinase, indirectly drives growth of tumors.

Alecensa, known chemically as alectinib, is the only lung cancer drug also approved for treating lung cancer that has spread to the brain.

Genentech, part of Swiss drugmaker Roche Group, will have a list price of about $12,500 per month before discounts negotiated with insurers.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News